A61K 47/6445
Haemoglobin
Official title: {Haemoglobin}
A61K47/6445 (Haemoglobin) appears on 80 US grants and 59 published applications in this corpus.
Search patents in A61K- Granted patents
- 80
- Published applications
- 59
- Assignees
- 38
- Inventors
- 142
- Latest grant
- 2 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 6 | 0 |
| 1996 | 1 | 0 |
| 1997 | 5 | 0 |
| 1998 | 19 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 5 | 0 |
| 2002 | 2 | 5 |
| 2003 | 1 | 2 |
| 2004 | 1 | 2 |
| 2005 | 7 | 3 |
| 2006 | 0 | 3 |
| 2007 | 2 | 4 |
| 2008 | 2 | 5 |
| 2009 | 1 | 3 |
| 2010 | 2 | 2 |
| 2011 | 0 | 0 |
| 2012 | 1 | 4 |
| 2013 | 2 | 1 |
| 2014 | 0 | 3 |
| 2015 | 4 | 1 |
| 2016 | 1 | 2 |
| 2017 | 2 | 3 |
| 2018 | 0 | 0 |
| 2019 | 1 | 2 |
| 2020 | 2 | 5 |
| 2021 | 1 | 2 |
| 2022 | 2 | 2 |
| 2023 | 2 | 1 |
| 2024 | 0 | 2 |
| 2025 | 1 | 0 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Cellular targeted label delivery system2 Dec 2025US 12,485,192 B2Cellis AG
- Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products30 May 2023US 11,660,286 B2EpicentRx, Inc.
- Hemoglobin-based therapeutic agents14 Feb 2023US 11,576,978 B2Cheer Global Limited
- Cellular targeted active ingredient delivery system11 Oct 2022US 11,464,879 B2Cellis AG
- Hemoglobin based oxygen carrier and method of preparation12 Apr 2022US 11,298,407 B2The Governing Council of the University of Toronto
- Isolated targeted delivery system for the treatment of ovarian cancer23 Jul 2026US 2026/0207519 A1
- Isolated targeted delivery system for the treatment of glioma2 Apr 2026US 2026/0091119 A1
- Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products14 Nov 2024US 2024/0374562 A1EpicentRx, Inc.
- Hemoglobin-based oxygen carriers and methods of making and using thereof26 Sep 2024US 2024/0316149 A1Ohio State Innovation Foundation
- Hemoglobin-Targeted Drug Delivery For The Treatment of Cancer22 Jun 2023US 2023/0190947 A1Therapure Biopharma Inc.
Most cited
By later US patents
- Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute96US 5,234,903 AEnzon, Inc. · 1993
- Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute74US 5,386,014 AEnzon, Inc. · 1995
- Production and use of multimeric hemoglobins64US 5,599,907 ASomatogen, Inc. · 1997
- Fractionation of polyalkylene oxide-conjugated hemoglobin solutions61US 5,312,808 AEnzon, Inc. · 1994
- Hemoglobins as drug delivery agents53US 5,679,777 ASomatogen, Inc. · 1997